Gene-modified dendritic cells for use in tumor vaccines

Human Gene Therapy

Volumn 11, Issue 6, 2000, Pages 797-806

  Kirk, Christopher J ^a   Mulé, James J ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BETA GALACTOSIDASE; CD14 ANTIGEN; CD34 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 7; LIPOSOME; LYMPHOTACTIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; PROTEIN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; VIRUS VECTOR;

DENDRITIC CELL; DNA MODIFICATION; GENE; GENE GUN; GENE TRANSFER; HUMAN; IMMUNIZATION; NONHUMAN; REVIEW; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CYTOKINES; DENDRITIC CELLS; DNA, VIRAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MICE;

ANIMALIA; MURINAE;

EID: 0034630499     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050015419     Document Type: Review

References (66)

1. AHUJA, S.S., MUMMIDI, S., MALECH, H.L., and AHUJA, S.K. (1998). Human dendritic cell (DC)-based anti-infective therapy: Engineering DCs to secrete functional IFN-gamma and IL-12. J. Immunol. 161, 868-876.
2. AHUJA, S.S., REDDICK, R.L., SATO, N., MONTALBO, E., KOSTECKI, V., ZHAO, W., DOLAN, M.J., MELBY, P.C., and AHUJA, S.K. (1999). Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J. Immunol. 163, 3890-3897.
3. AICHER, A., WESTERMANN, J., CAYEUX, S., WILLIMSKY, G., DAEMEN, K., BLANKENSTEIN, T., UCKERT, W., DORKEN, B., and PEZZUTTO, A. (1997). Successful retroviral mediated transduction of a reporter gene in human dendritic cells: Feasibility of therapy with gene-modified antigen presenting cells. Exp. Hematol. 25, 39-44.
4. ALIJAGIC, S., MOLLER, P., ARTUC, M., JURGOVSKY, K., CZARNETZKI, B.M., and SCHADENDORF (1995). Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. Eur. J. Immunol. 25, 3100-3107.
5. ARTHUR, J.F., BUTTERFIELD, L.H., ROTH, M.D., BUI, L.A., KIERTSCHER, S.M., LAU, R., DUBINETT, S., GLASPY, J., McBRIDE, W.H., and ECONOMOU, J.S. (1997). A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 4, 17-25.
6. BANCHEREAU, J., and STEINMAN, R.M. (1998). Dendritic cells and the control of immunity. Nature (London) 392, 245-252.
7. BENDER, A., SAPP, M., SCHULER, G., STEINMAN, R.M., and BHARDWAJ, N. (1996). Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods 196, 121-135.
8. BERGELSON, J.M., CUNNINGHAM, J.A., DROGUETT, G., KURT-JONES, E.A., KRITHIVAS, A., HONG, J.S., HORWITZ, M.S., CROWELL, R.L., and FINBERG, R.W. (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323.
9. BERGELSON, J.M., KRITHIVAS, A., CELI, L., DROGUETT, G., HORWITZ, M.S., WICKHAM, T., CROWELL, R.L., and FINBERG, R.W. (1998). The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J. Virol. 72, 415-419.
10. BROSSART, P., GOLDRATH, A.W., BUTZ, E.A., MARTIN, S., and BEVAN, M.J. (1997). Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol. 158, 3270-3276.
11. BROWN, M., DAVIES, D.H., SKINNER, M.A., BOWEN, G., HOLLINGSWORTH, S.J., MUFTI, G.J., ARRAND, J.R., and STACEY, S.N. (1999). Antigen gene transfer to cultured human dendritic cells using recombinant avipoxvirus vectors. Cancer Gene Ther. 6, 238-245.
12. BUTTERFIELD, L.H., JILANI, S.M., CHAKRABORTY, N.G., BUI, L.A., RIBAS, A., DISSETTE, V.B., LAU, R., GAMRADT, S.C., GLASPY, J.A., McBRIDE, W.H., MUKHERJI, B., and ECONOMOU, J.S. (1998). Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J. Immunol. 161, 5607-5613.
13. CAO, X., ZHANG, W., HE, L., XIE, Z., MA, S., TAO, Q., YU, Y., HAMADA, H., and WANG, J. (1998). Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. J. Immunol. 161, 6238-6244.
14. CAO, X., ZHANG, W., WANG, J., ZHANG, M., HUANG, X., HAMADA, H., and CHEN, W. (1999). Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Immunology 97, 616-625.
15. COFFIN, R.S., THOMAS, S.K., THOMAS, N.S., LILLEY, C.E., PIZZEY, A.R., GRIFFITHS, C.H., GIBB, B.J., WAGSTAFF, M.J., INGES, S.J., BINKS, M.H., CHAIN, B.M., THRASHER, A.J., RUTAULT, K., and LATCHMAN, D.S. (1998). Pure populations of transduced primary human cells can be produced using GFP expressing herpes virus vectors and flow cytometry. Gene Ther. 5, 718-722.
16. COHEN, P.J., COHEN, P.A., ROSENBERG, S.A., KATZ, S.I., and MULÉ, J.J. (1994). Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Eur. J. Immunol. 24, 315-319.
17. CURIEL-LEWANDROWSKI, C., MAHNKE, K., LABEUR, M., ROTERS, B., SCHMIDT, W., GRANSTEIN, R.D., LUGER, T.A., SCHWARZ, T., and GRABBE, S. (1999). Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. J. Immunol. 163, 174-183.
18. CYSTER, J.G. (1999). Chemokines and the homing of dendritic cells to the T cell areas of lymphoid organs. J. Exp. Med. 189, 447-450.
19. DE VEERMAN, M., HEIRMAN, C., VAN, M.S., DEVOS, S., CORTHALS, J., MOSER, M., and THIELEMANS, K. (1999). Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. J. Immunol. 162, 144-151.
20. DIEBOLD, S.S., KURSA, M., WAGNER, E., COTTEN, M., and ZENKE, M. (1999a). Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells. J. Biol. Chem. 274, 19087-19094.
21. DIEBOLD, S.S., LEHRMANN, H., KURSA, M., WAGNER, E., COTTEN, M., and ZENKE, M. (1999b). Efficient gene delivery into human dendritic cells by adenovirus polyethylenimine and mannose polyethylenimine transfection. Hum. Gene Ther. 10, 775-786.
22. DIETZ, A.B., and VUK-PAVLOVIC, S. (1998). High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 91, 392-398.
23. FIELDS, R.C., OSTERHOLZER, J.J., FULLER, J.A., THOMAS, E.K., GERAGHTY, P.J., and MULÉ, J.J. (1998). Comparative analysis of murine dendritic cells derived from spleen and bone marrow. J. Immunother. 21, 323-339.
24. HART, D.N. (1997). Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood 90, 3245-3287.
25. HSU, F.J., BENIKE, C., FAGNONI, F., LILES, T.M., CZERWINSKI, D., TAIDI, B., ENGLEMAN, E.G., and LEVY, R. (1996). Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2, 52-58.
26. ISHIDA, T., CHADA, S., STIPANOV, M., NADAF, S., CIERNIK, F.I., GABRILOVICH, D.I., and CARBONE, D.P. (1999). Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin. Exp. Immunol. 117, 244-251.
27. + dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity. Gene Ther. 7, 249.
28. KAPLAN, J.M., YU, Q., PIRAINO, S.T., PENNINGTON, S.E., SHANKARA, S., WOODWORTH, L.A., and ROBERTS, B.L. (1999). Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J. Immunol. 163, 699-707.
29. KIM, C.J., PREVETTE, T., CORMIER, J., OVERWIJK, W., RODEN, M., RESTIFO, N.P., ROSENBERG, S.A., and MARINCOLA, P.M. (1997). Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. J. Immunother. 20, 276-286.
30. KUNIYOSHI, J.S., KUNIYOSHI, C.J., LIM, A.M., WANG, F.Y., BADE, E.R., LAU, R., THOMAS, E.K., and WEBER, J.S. (1999). Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells. Cell. Immunol. 193, 48-58.
31. LABEUR, M.S., ROTERS, B., PERS, B., MEHLING, A., LUGER, T.A., SCHWARZ, T., and GRABBE, S. (1999). Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 162, 168-175.
32. LUFT, T., PANG, K.C., THOMAS, E., HERTZOG, P., HART, D.N., TRAPANI, J., and CEBON, J. (1998). Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol. 161, 1947-1953.
33. McARTHUR, J.G., and MULLIGAN, R.C. (1998). Induction of protective anti-tumor immunity by gene-modified dendritic cells. J. Immunother. 21, 41-47.
34. MILLER, P.W., SHARMA, S., STOLINA, M., BUTTERFIELD, L.H., LUO, J., LIN, Y., DOHADWALA, M., BATRA, R.K., WU, L., ECONOMOU, J.S., and DUBINETT, S.M. (2000). Intratumoral administration of adenoviral interleukin-7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor cradication. Hum. Gene Ther. 11, 53-65.
35. MORSE, M.A., LYERLY, H.K., GILBOA, E., THOMAS, E., and NAIR, S.K. (1998). Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res. 58, 2965-2968.
36. MULDERS, P., PANG, S., DANNULL, J., KABOO, R., HINKEL, A., MICHEL, T., TSO, C.L., ROTH, M., and BELLDEGRUN, A. (1998). Highly efficient and consistent gene transfer into dendritic cells utilizing a combination of ultraviolet-irradiated adenovirus and poly(L-lysine) conjugates. Cancer Res. 58, 956-961.
37. NESTLE, F.O., ALIJAGIC, S., GILLIET, M., SUN, Y., GRABBE, S., DUMMER, R., BURG, G., and SCHADENDORF, D. (1998). Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328-332.
38. NISHIOKA, Y., HIRAO, M., ROBBINS, P.D., LOTZE, M.T., and TAHARA, H. (1999). Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res. 59, 4035-4041.
39. OSTERROTH, F., GARBE, A., FISCH, P., and VEELKEN, H. (2000). Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells. Blood 95, 1342.
40. PEREZ-DIEZ, A., BUTTERFIELD, L.H., LI, L., CHAKRABORTY, N.G., ECONOMOU, J.S., and MUKHERJI, B. (1998). Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene. Cancer Res. 58, 5305-5309.
41. PHILIP, R., ALTERS, S.E., BRUNETTE, E., ASHTON, J., GADEA, J., YAU, J., LEBKOWSKI, J., and PHILIP, M. (2000). Dendritic cells loaded with MART-1 peptide or infected with adenoviral construct are functionally equivalent in the induction of tumor-specific cytotoxic T lymphocyte responses in patients with melanoma. J. Immunother. 23, 168.
42. REA, D., SCHAGEN, F.H., HOEBEN, R.C, MEHTALI, M., HAVENGA, M.J., TOES, R.E., MELIEF, C.J., and OFFRINGA, R. (1999). Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J. Virol. 73, 10245-10253.
43. REEVES, M.E., ROYAL, R.E., LAM, J.S., ROSENBERG, S.A., and HWO, P. (1996). Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res. 56, 5672.
44. RIBAS, A., BUTTERFIELD, L.H., McBRIDE, W.H., JILANI, S.M., BUI, L.A., VOLLMER, C.M., LAU, R., DISSETTE, V.B., HU, B., CHEN, A.Y., GLASPY, J.A., and ECONOMOU, J.S. (1997). Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res. 57, 2865-2869.
45. RIBAS, A., BUTTERFIELD, L.H., HU, B., DISSETTE, V.B., CHEN, A.Y., KOH, A., AMARNANI, S.N., GLASPY, J.A., McBRIDE, W.H., and ECONOMOU, J.S. (2000). Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J. Immunother. 23, 59.
46. ROMANI, N., REIDER, D., HEUER, M., EBNER, S., KAMPGEN, E., EIBL, B., NIEDERWIESER, D., and SCHULER, G. (1996). Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J. Immunol. Methods 196, 137-151.
47. + T cell help to elicit antitumor immunity: Implications for the clinical use of dendritic cells. J. Immunol. 164, 1243.
48. SCHULER, G., and STEINMAN, R.M. (1997). Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186, 1183-1187.
49. SONDERBYE, L., FENG, S., YACOUBIAN, S., BUEHLER, H., AHSAN, N., MULLIGAN, R., and LANGHOFF, E. (1998). In vivo and in vitro modulation of immune stimulatory capacity of primary dendritic cells by adenovirus-mediated gene transduction. Exp. Clin. Immunogenet. 15, 100-111.
50. SONG, W., KONG, H.L., CARPENTER, H., TORII, H., GRANSTEIN, R., RAFII, S., MOORE, M.A., and CRYSTAL, R.G. (1997). Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186, 1247-1256.
51. SPECHT, J.M., WANG, G., DO, M.T., LAM, J.S., ROYAL, R.E., REEVES, M.E., ROSENBERG, S.A., and HWU, P. (1997). Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186, 1213-1221.
52. TALMOR, M., MIRZA, A., TURLEY, S., MELLMAN, I., HOFFMAN, L.A., and STEINMAN, R.M. (1998). Generation or large numbers of immature and mature dendritic cells from rat bone marrow cultures. Eur. J. Immunol. 28, 811-817.
53. TEPPER, R.I., and MULÉ, J.J. (1994). Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene Ther. 5, 153-164.
54. TILLMAN, B.W., DE GRUIJL, T.D., LUYKX-DE BAKKER, S.A., SCHEPER, R.J., PINEDO, H.M., CURIEL, T.J., GERRITSEN, W.R., and CURIEL, D.T. (1999). Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J. Immunol. 162, 6378-6383.
55. TIMMERMAN, J.M., and LEVY, R. (1999). Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50, 507-529.
56. TOES, R.E., OSSENDORP, F., OFFRINGA, R., and MELIEF, C.J. (1999). CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189, 753-756. [Comment].
57. TUTING, T., DELEO, A.B., LOTZE, M.T., and STORKUS, WJ. (1997). Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur. J. Immunol. 27, 2702-2707.
58. TUTING, T., WILSON, C.C., MARTIN, D.M., KASAMON, Y.L., ROWLES, J., MA, D.I., SLINGLUFF, C.L., JR., WAGNER, S.N., VAN DER BRUGGER, B.P., BAAR, J., LOTZE, M.T., and STORKUS, W.J. (1998). Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by co-transfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α. J. Immunol. 160, 1139-1147.
59. VAN TENDELOO, V.F., SNOECK, H.W., LARDON, F., VANHAM, G.L., NIJS, G., LENJOU, M., HENDRIKS, L., VAN BROECKHOVEN, C., MOULIHN, A., RODRIGUS, I., VERDONK, P., VAN BOCKSTAELE, D.R., and BERNEMAN, Z.N. (1998). Nonviral transfection of distinct types of human dendritic cells: High-efficiency gene transfer by electroporation into hematopoietic progenitor - but not monocyte-derived dendritic cells. Gene Ther. 5, 700-707.
60. WAN, Y., EMTAGE, P., ZHU, Q., FOLEY, R., PILON, A., ROBERTS, B., and GAULDIE, J. (1999). Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Cell. Immunol. 198, 131.
61. WAN, Y., BRAMSON, J., CARTER, R., GRAHAM, F., and GAULDIE, J. (1997). Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum. Gene Ther. 8, 1355-1363.
62. WESTERMANN, J., AICHER, A., QIN, Z., CAYEUX, Z., DAEMEN, K., BLANKENSTEIN, T., DORKEN, B., and PEZZUTTO, A. (1998). Retroviral interleukin-7 gene transfer into human dendritic cells enhances T cell activation. Gene Ther. 5, 264-271.
63. WICKHAM, T.J., MATHIAS, P., CHERESH, D.A., and NEMEROW, G.R. (1993). Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73, 309-319.
64. WONG, B.R., JOSIEN, R., LEE, S.Y., SAUTER, B., LI, H.L., STEINMAN, R.M., and CHOI, Y. (1997). TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186, 2075-2080.
65. ZHANG, W., HE, L., YUAN, Z., XIE, Z., WANG, J., HAMADA, H., and CAO, X. (1999). Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin. Hum. Gene Ther. 10, 1151-1161.
66. ZHONG, L., GRANELLI-PIPERNO, A., CHOI, Y., and STEINMAN, R.M. (1999). Recombinant adenovirus is an efficient and nonperturbing genetic vector for human dendritic cells. Eur. J. Immunol. 29, 964-972.